JPRN-UMIN000009476
Completed
Phase 2
A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancer - A phase II study of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancer (TCOG LC-1202)
Conditionsnon-squamous non-small-cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non-squamous non-small-cell lung cancer
- Sponsor
- The Tokyo cooperative oncology group
- Enrollment
- 39
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Symptomatic brain metastases 2\.history of active double cancer within 5 years 3\.Current history of hemosputum or hemoptysis 4\.Have possibly complication related to bleeding episode 5\.Receiving anticoagulant drug (including Aspirin over 325mg/day) 6\.Great vessel involvement 7\.Have received radiation therapy to lesions of lung 8\.Pleural effusion,peritoneal fluid, and pericardial fluid 9\.Serious complications 10\.Perforation of the digestive tract or history of the perforation of the digestive tract within the past one year 11\.Uncontrollable Hypertension 12\.Interstitial pneumonia or pulmonary fibrosis detectable on X ray 13\.Proven or suspected infections diseases 14\.Watery diarrhea or Chronic constipation 15\.Under treatment by flucytosine 16\.Hypersensitivity of Protocol agents 17\.History of pregnancy or lactation and no intention to practice birth control 18\.Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with metastatic melanomaStage IV MelanomaMedDRA version: 14.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-019033-98-DEniversity Clinical Center of Tuebingen
Active, not recruiting
Phase 2
Phase II study of allogeneic transplantation using transplant-lite conditioning regimesMetastatic renal cancerHaematological malignancyCancer - Haematological diseasesACTRN12605000536662Dr James Morton80
Recruiting
Phase 2
Trifluridine/tipiracil (FTD/TPI) plus ramucirumab (Ram) for advanced gastric cancergastric cancerGastric cancerJPRN-jRCTs041210105Kodera Yasuhiro32
Completed
Phase 2
Phase II study investigating efficacy and safety of TFTD plus bevacizumab by RAS mutation status in patients with unresectable advanced or recurrent colorectal cancer refractory or intolerant to standard chemotherapyJPRN-UMIN000030077Japanese Foundation for Multidisciplinary Treatment of Cancer102
Active, not recruiting
Not Applicable
A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combination with lapatinib for metastatic diseasemetastatic breast cancerEUCTR2009-016826-15-ATCECOG30